Discovery

ImmunoPrecise Antibodies Ltd operates globally to offer a continuum of superior antibody services, transforming the face of therapeutic and diagnostic discovery by decreasing turnaround time and risk, and promoting clinical success.

Therapeutics, Diagnostics, & Research

Our elite team has revolutionized antibody discovery. We are the true end-to-end antibody discovery CRO operating from lead characterization, optimization, engineering and in vivo analyses, delivering superior products. We succeed because we have the expertise and experience to provide high-throughput services across the full antibody discovery value chain.

Read more about our end-to-end services

Our elite team has revolutionized antibody discovery. We are the true end-to-end antibody discovery CRO operating from lead characterization, optimization, engineering and in vivo analyses, delivering superior products. We succeed because we have the expertise and experience to provide high-throughput services across the full antibody discovery value chain.

Read more about our end-to-end services

Our next generation of antibody discovery was developed to deliver the most therapeutically relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials. We offer proprietary antibody discovery technologies, driven by rigorous computational analyses, feeding our B cell Select™, phage display, and hybridoma generation using semi-solid media and clone picking, to deliver high affinity antibodies. We have the experience with alternative species or strains, including transgenic animals or knock-out strains, and

use our Abthena™ bispecific antibody platform to develop products for your therapeutic pipeline.

Antibodies are also critical tools for the diagnosis of disease. Antibodies recognizing unique antigenic determinants on pathogens, biomarkers, or even an antibody itself (anti-idiotypic) can be developed in multiple species.

In many research areas, the specificity of the antibody binding is highly important–if not critical-for the progress of the research.

At ImmunoPrecise, we offer multiple immunization technologies to deliver poly- or monoclonal antibodies from multi-species, tested in your intended application and delivered in qualities and quantities of your choice.

We pride ourselves on our high customer satisfaction, and our clients have grown accustomed to receiving very thorough and professional services, with a fast turnaround time. We customize programs to generate antibodies that meet each of our clients’ specifications.

B cell Select™

Supported by decades of experience, ImmunoPrecise Antibodies’ B-Cell Select™ platform allows for the interrogation of a greater diversity of an animal’s antibody repertoire than otherwise possible. This proprietary platform is species independent, allowing for the generation of antibodies from samples not possible using other methods. B-Cell Select™, which can develop antibodies from any species (including human) and from any tissue, explores the entire antibody repertoire, and identifies antibodies for anything that is possible in an animal’s immune repertoire including any protein class, complex therapeutic targets, post-translational modifications, and small molecules.

The B-Cell Select platform enables the interrogation of ten million blood cells to generate native, monoclonal antibodies from immunized animals that specifically target an antigen and allow for the rapid selection of top candidates, drastically increasing the success rate of an antibody discovery program. The platform also harnesses the power of the immune system to generate natural pairing of the antibodies produced by selected B-cells.

Abthena™ Bispecifics

Our proprietary bispecific Abthena™ technology complements our diverse discovery process, integrating seamlessly with our Artemis™ Intelligence Metadata (AIM)™ capabilities, to enable rapid turnaround on additional algorithmic outputs in therapeutic antibody optimization, stability, affinity, and manufacturability.

We have designed an advanced discovery platform for wild-type and fully human bispecific antibody components, which allows for the generation of heterodimer, optimized, IgG backbones with validated binding attributes. Abthena™ produces yields comparable to its monospecific equivalents, with a high degree of dimer formation.

Phage Display

Our phage display approach is based on building custom immune libraries from multiple species, including transgenic animals, or the selection of antigen-specific recombinant antibody fragments from our proprietary human or llama phage libraries. Our proprietary libraries have been made from human patient and naïve (scFv) repertoires, as well as from naïve llama (VHH) repertoires. Custom immune libraries are prepared from blood, spleen, lymph nodes, and bone marrow of immunized animals or humans and capture the entire immune repertoire for panning, rescue, and identification of unique antibodies with pre-specified characteristics.

Transgenics

We are a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials. The use of transgenic animals producing fully human idiotypes eliminates the need for a humanization step in the race for a cure. At ImmunoPrecise we successfully apply the transgenic animal of our client’s choice to our hybridoma, B cell Select™ and DeepDisplay™ technologies.

Hybridoma

As leaders in hybridoma development, ImmunoPrecise offers cutting edge antibody development services including, Rapid Prime immunization, DNA immunization (NonaVac™), cell-based immunization (ModiVacc™), electro-fusion and hybridoma generation using semi-solid media and clone picking, as well as high throughput, multiplexed screening methods. With ImmunoProtect™, the DNA sequence of your antibody will be determined and can be used to express your antibody recombinantly.

Humanization

Animal-derived monoclonal antibodies can elicit human anti-animal antibody responses in patients. Therefore, it is usually necessary to replace the animal content with the corresponding human amino acid residues. We provide a robust and efficient antibody humanization service, which consistently retains affinity and specificity levels. Our approach is based on state of the art in silico antibody modeling using our Artemis™ Intelligence Metadata (AIM)™ capabilities to identify essential framework and CDR residues for grafting onto a human antibody framework.